Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

281

Participants

Timeline

Start Date

June 16, 2015

Primary Completion Date

November 30, 2019

Study Completion Date

November 30, 2029

Conditions
Multiple Myeloma
Interventions
PROCEDURE

Autologous Stem Cell Transplant (ASCT)

Randomisation to melphalan conditioned autologous stem cell transplant

DRUG

Consolidation with 4 cycles of CarCyDex

Randomisation to 4 further cycles of Carfilzomib, Cyclophosphamide and Dexamethasone for responding patients following 4 cycles of induction chemotherapy

Trial Locations (20)

RM7 0AG

Queen's Hospital, Romford

BA1 3NG

Royal United Hospital, Bath

B9 5SS

Birmingham Heartlands Hospital, Birmingham

Unknown

NHS Lanarkshire, Bothwell

Bradford Royal Infirmary, Bradford

University College London Hospital, London

Maidstone and Tunbridge Wells, Maidstone

Royal Stoke University Hospital, Stoke

City Hospital Sunderland, Sunderland

CT1 3NH

Kent and Canterbury Hospital, Canterbury

CF14 4XW

University Hospital of Wales, Cardiff

ME7 5NY

Medway NHS Foundation Trust, Gillingham

LS9 7TF

St James' Hospital, Leeds

EC1A 7BE

St Bartholomew's Hospital, London

EN5 3DJ

Barnet Hospital, London

SE1 9RT

Guy's Hospital, London

SE5 9RS

King's College Hospital, London

SW17 0QT

St George's Hospital, London

OX3 7LE

Churchill Hospital, Oxford

S10 2SB

Royal Hallamshire Hospital, Sheffield

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

University College, London

OTHER